Form D · Pharmaceuticals
Aptinyx Inc.
Evanston, IL · CIK 0001674365
Offering snapshot reported Dec 21, 2017 · SEC filing
- Reported sold
- $70M Offering amount: $70M
- Investors reported
- 63 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 15, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 21, 2017 | Initial | $70,000,000 | No comparison | 63 | SEC filing |
| May 19, 2016 | Initial | $24,999,999 | No comparison | 48 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-301461
Source: Form D, filed Dec 21, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick Enright | Director |
| Wilbur H. Gantz Iii | Director |
| Terry P. Gould | Director |
| Ashish Khanna | Executive |
| Andrew D. Kidd | Executive |
| Adam M. Koppel | Director |
| Torsten M. Madsen | Executive |
| Joseph R. Moskal | Executive |
| Liam Ratcliffe | Director |
| Norbert G. Riedel | Director, Executive |
| James Topper | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1801 Maple Avenue Suite 4300
Evanston, IL, 60201
Evanston, IL, 60201